236 related articles for article (PubMed ID: 38066546)
1. Pediatric glioma histone H3.3 K27M/G34R mutations drive abnormalities in PML nuclear bodies.
Voon HPJ; Hii L; Garvie A; Udugama M; Krug B; Russo C; Chüeh AC; Daly RJ; Morey A; Bell TDM; Turner SJ; Rosenbluh J; Daniel P; Firestein R; Mann JR; Collas P; Jabado N; Wong LH
Genome Biol; 2023 Dec; 24(1):284. PubMed ID: 38066546
[TBL] [Abstract][Full Text] [Related]
2. Low-Grade Gemistocytic Morphology in H3 G34R-Mutant Gliomas and Concurrent K27M Mutation: Clinicopathologic Findings.
Morris M; Driscoll M; Henson JW; Cobbs C; Jiang L; Gocke CD; Chen L; Rodriguez FJ
J Neuropathol Exp Neurol; 2020 Oct; 79(10):1038-1043. PubMed ID: 32954438
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
Castel D; Philippe C; Kergrohen T; Sill M; Merlevede J; Barret E; Puget S; Sainte-Rose C; Kramm CM; Jones C; Varlet P; Pfister SM; Grill J; Jones DTW; Debily MA
Acta Neuropathol Commun; 2018 Nov; 6(1):117. PubMed ID: 30396367
[TBL] [Abstract][Full Text] [Related]
4. Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma.
Minasi S; Baldi C; Gianno F; Antonelli M; Buccoliero AM; Pietsch T; Massimino M; Buttarelli FR
Childs Nerv Syst; 2021 Mar; 37(3):809-818. PubMed ID: 33128602
[TBL] [Abstract][Full Text] [Related]
5. The role of histone modifications and telomere alterations in the pathogenesis of diffuse gliomas in adults and children.
Lee J; Solomon DA; Tihan T
J Neurooncol; 2017 Mar; 132(1):1-11. PubMed ID: 28064387
[TBL] [Abstract][Full Text] [Related]
6. Base-resolution methylomes of gliomas bearing histone H3.3 mutations reveal a G34 mutant-specific signature shared with bone tumors.
Sangatsuda Y; Miura F; Araki H; Mizoguchi M; Hata N; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Arai Y; Yoshida A; Shibata T; Yoshimoto K; Iihara K; Ito T
Sci Rep; 2020 Sep; 10(1):16162. PubMed ID: 32999376
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal H3.3 gene editing identifies K27M and G34R mechanisms in pediatric glioma including NOTCH signaling.
Chen KY; Bush K; Klein RH; Cervantes V; Lewis N; Naqvi A; Carcaboso AM; Lechpammer M; Knoepfler PS
Commun Biol; 2020 Jul; 3(1):363. PubMed ID: 32647372
[TBL] [Abstract][Full Text] [Related]
8. Histone H3.3K27M Mobilizes Multiple Cancer/Testis (CT) Antigens in Pediatric Glioma.
Deng H; Zeng J; Zhang T; Gong L; Zhang H; Cheung E; Jones C; Li G
Mol Cancer Res; 2018 Apr; 16(4):623-633. PubMed ID: 29453317
[TBL] [Abstract][Full Text] [Related]
9. Incidence and clinicopathologic features of H3 K27M mutations in adults with radiographically-determined midline gliomas.
Schreck KC; Ranjan S; Skorupan N; Bettegowda C; Eberhart CG; Ames HM; Holdhoff M
J Neurooncol; 2019 May; 143(1):87-93. PubMed ID: 30864101
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours.
Haque F; Varlet P; Puntonet J; Storer L; Bountali A; Rahman R; Grill J; Carcaboso AM; Jones C; Layfield R; Grundy RG
Acta Neuropathol Commun; 2017 Jun; 5(1):45. PubMed ID: 28587626
[TBL] [Abstract][Full Text] [Related]
11. Promyelocytic leukemia (PML) nuclear bodies (NBs) induce latent/quiescent HSV-1 genomes chromatinization through a PML NB/Histone H3.3/H3.3 Chaperone Axis.
Cohen C; Corpet A; Roubille S; Maroui MA; Poccardi N; Rousseau A; Kleijwegt C; Binda O; Texier P; Sawtell N; Labetoulle M; Lomonte P
PLoS Pathog; 2018 Sep; 14(9):e1007313. PubMed ID: 30235352
[TBL] [Abstract][Full Text] [Related]
12. PML is recruited to heterochromatin during S phase and represses DAXX-mediated histone H3.3 chromatin assembly.
Shastrula PK; Sierra I; Deng Z; Keeney F; Hayden JE; Lieberman PM; Janicki SM
J Cell Sci; 2019 Mar; 132(6):. PubMed ID: 30796101
[TBL] [Abstract][Full Text] [Related]
13. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.
Khuong-Quang DA; Buczkowicz P; Rakopoulos P; Liu XY; Fontebasso AM; Bouffet E; Bartels U; Albrecht S; Schwartzentruber J; Letourneau L; Bourgey M; Bourque G; Montpetit A; Bourret G; Lepage P; Fleming A; Lichter P; Kool M; von Deimling A; Sturm D; Korshunov A; Faury D; Jones DT; Majewski J; Pfister SM; Jabado N; Hawkins C
Acta Neuropathol; 2012 Sep; 124(3):439-47. PubMed ID: 22661320
[TBL] [Abstract][Full Text] [Related]
14. Histone H3 mutations in pediatric brain tumors.
Liu X; McEachron TA; Schwartzentruber J; Wu G
Cold Spring Harb Perspect Biol; 2014 Apr; 6(4):a018689. PubMed ID: 24691963
[TBL] [Abstract][Full Text] [Related]
15. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
[TBL] [Abstract][Full Text] [Related]
16. Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation.
Aboian MS; Solomon DA; Felton E; Mabray MC; Villanueva-Meyer JE; Mueller S; Cha S
AJNR Am J Neuroradiol; 2017 Apr; 38(4):795-800. PubMed ID: 28183840
[TBL] [Abstract][Full Text] [Related]
17. Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations.
Solomon DA; Wood MD; Tihan T; Bollen AW; Gupta N; Phillips JJ; Perry A
Brain Pathol; 2016 Sep; 26(5):569-80. PubMed ID: 26517431
[TBL] [Abstract][Full Text] [Related]
18. Histone H3 mutations--a special role for H3.3 in tumorigenesis?
Kallappagoudar S; Yadav RK; Lowe BR; Partridge JF
Chromosoma; 2015 Jun; 124(2):177-89. PubMed ID: 25773741
[TBL] [Abstract][Full Text] [Related]
19. Chromatin mutations in pediatric high grade gliomas.
Voon HPJ; Wong LH
Front Oncol; 2022; 12():1104129. PubMed ID: 36686810
[TBL] [Abstract][Full Text] [Related]
20. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location.
Karremann M; Gielen GH; Hoffmann M; Wiese M; Colditz N; Warmuth-Metz M; Bison B; Claviez A; van Vuurden DG; von Bueren AO; Gessi M; Kühnle I; Hans VH; Benesch M; Sturm D; Kortmann RD; Waha A; Pietsch T; Kramm CM
Neuro Oncol; 2018 Jan; 20(1):123-131. PubMed ID: 29016894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
